



## Ibrutinib in Chronic Lymphocytic Leukemia

Guest Editor:

**Dr. Stefania Fiorcari**

Department of Oncology and  
Hematology, Division of Immuno-  
Hematology and Trasfusione  
Medicine, Azienda Ospedaliero  
Universitaria, Policlinico of  
Modena, via Del Pozzo 71, 41124  
Modena, Italy

Deadline for manuscript  
submissions:

**30 September 2024**

### Message from the Guest Editor

Dear Colleagues,

Introduction of Bruton Tyrosine kinase (BTK) inhibitors in the clinical practice has deeply altered the treatment paradigm of Chronic Lymphocytic Leukemia (CLL) patients. In particular, ibrutinib is the first BTK inhibitor used in the treatment of CLL that is able to bind covalently to cysteine residue (C481) in the ATP-binding domain of the BTK kinase leading to inhibition of its enzymatic activity. Inhibition of BTK prevents downstream activation of the BCR pathway affecting cell growth, proliferation, homing and survival of the leukemic B cells.

Although ibrutinib has shown excellent effects on CLL cell component inducing mobilization of lymphocytes from tissue into the blood with the consequent cell death, recently different studies have demonstrated the on-target effects on off-tumor cells related to tumor microenvironment.

This Special Issue aims to summarize the current knowledge and cutting-edge research on BTK inhibitors in CLL.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)